Article Text

PDF

CP-072 Cardiovascular risk associated with the use of non steroidal anti-inflammatory drugs. Cohort study
  1. JL Sánchez Serrano1,
  2. JM Tenias Burillo2,
  3. MC Conde Garcia1,
  4. B Proy Vega1,
  5. MT Gomez LLuch1,
  6. JC Valenzuela Gamez1
  1. 1Hospital G La Mancha Centro, Pharmacy, Alcazar de San Juan, Spain
  2. 2Hospital G La Mancha Centro, Investigation, Alcazar de San Juan, Spain

Abstract

Background Since the clinical trial VIGOUR, in which the use of rofecoxib was proved to be connected to a larger number of cardiovascular accidents, an increase in cardiovascular diseases connected to the use of non-steroidal anti-inflammatory drugs has been observed.

Purpose This study intends to evaluate cardiovascular impact related to the use of non steroidal anti-inflammatory drugs.

Material and methods A retrospective observational study of a clinical cohort over 5 years was done in which all patients older than 18 years (n = 116 686) were included. The statistical analysis was done estimating the incidence of acute coronary syndrome in relation to exposure time. The risk associated with the consumption of non-steroidal anti-inflammatory drugs was made by Poisson regression adjusting for sex and age.

Results The connexion between acute coronary syndrome and the use of anti-inflammatory drugs was positive and significant (RR 3.64; 95% CI 2.94 to 4.52; p < 0.001). The cardiovascular risk was higher for alkanones (RR 18; 95% CI 2.53 to 127; p = 0.004), followed by propionoicos (RR 2.58; 95% CI 2.16 to 3.69; p < 0.001), arylacetic (RR 1.88; 95% CI 1.6 to 2.22; p < 0.001) and finally coxib (RR 1.55; 95% CI 1.25 to 1.92; p < 0.001); in other anti-inflammatories, no increased cardiovascular risk was observed.

Conclusion The use of non steroidal anti-inflammatory drugs has been connected to a higher risk of cardiovascular accidents; these drugs must not be consumed for a long time or at high doses.

References and/or Acknowledgements

  1. García Rodríguez LA, González-Pérez A, et al. NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PLoS One 2011;6:e16780

  2. Varas-Lorenzo C, Castellsague J, et al. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf 2009;18:1016-25

  3. García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008;11(52):1628-36

References and/or AcknowledgementsNo conflict of interest.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.